Biomarkers in Drug Discovery and Development: A Handbook of Practice, Application, and Strategy - Hardcover

Hardcover

ISBN 10: 1119187508 ISBN 13: 9781119187509

Verlag: Wiley, 2020

Inhaltsangabe

This book continues the legacy of a well-established reference within the pharmaceutical industry – providing perspective, covering recent developments in technologies that have enabled the expanded use of biomarkers, and discussing biomarker characterization and validation and applications throughout drug discovery and development.

• Explains where proper use of biomarkers can substantively impact drug development timelines and costs, enable selection of better compounds and reduce late stage attrition, and facilitate personalized medicine
• Helps readers get a better understanding of biomarkers and how to use them, for example which are accepted by regulators and which still non-validated and exploratory
• Updates developments in genomic sequencing, and application of large data sets into pre-clinical and clinical testing; and adds new material on data mining, economics, and decision making, personal genetic tools, and wearable monitoring
• Includes case studies of biomarkers that have helped and hindered decision making
• Reviews of the first edition:
  "If you are interested in biomarkers, and it is difficult to imagine anyone reading this who wouldn't be, then this book is for you." (ISSX) and "...provides a good introduction for those new to the area, and yet it can also serve as a detailed reference manual for those practically involved in biomarker implementation." (ChemMedChem)

Über diesen Titel

Über die Autorin bzw. den Autor

RAMIN RAHBARI, MS, MBA, is an expert in biomarkers at Innovative Scientific Management and has previously held similar consulting and research positions at IBM, Cognizant and Pfizer.

JONATHAN VAN NIEWAAL, MBA, is Technology Principal at Innovative Scientific Management and has held software development and technology delivery roles in the healthcare, financial services, and technology industries.

MICHAEL R. BLEAVINS, PHD, DABT, is the founder of White Crow Innovation, LLC, a Michigan-based drug development consulting company, and cofounder of Michigan Technology and Research Institute.

Von der hinteren Coverseite

Reviews of the first edition:

"If you are interested in biomarkers, and it is difficult to imagine anyone reading this who wouldn't be, then this book is for you." (ISSX)

"…Provides a good introduction for those new to the area, and yet it can also serve as a detailed reference manual for those practically involved in biomarker implementation." (ChemMedChem)

As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. Continuing the legacy of a well-established pharmaceutical industry reference, the second edition of Biomarkers in Drug Discovery and Development provides perspective, covers recent technological developments, and discusses biomarker characterization and validation.

The chapters overview the areas where proper use of biomarkers can substantively impact drug development timelines and costs, enable the selection of better compounds, reduce late stage attrition, and facilitate personalized medicine. Contributing authors from the frontlines of industrial research and development present case studies of biomarkers that have helped and hindered decision making. The new edition updates existing information with developments in genomic sequencing and application of large data sets into pre-clinical and clinical testing; and introduces substantial new materials on data mining, economics, and decision making.

With such significant expansion and revision, Biomarkers in Drug Discovery and Development, Second Edition remains a key resource for biotechnology and major pharmaceutical companies, and their efforts to improve and expedite drug development.

Aus dem Klappentext

Reviews of the first edition:

"If you are interested in biomarkers, and it is difficult to imagine anyone reading this who wouldn't be, then this book is for you." (ISSX)

"…Provides a good introduction for those new to the area, and yet it can also serve as a detailed reference manual for those practically involved in biomarker implementation." (ChemMedChem)

As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. Continuing the legacy of a well-established pharmaceutical industry reference, the second edition of Biomarkers in Drug Discovery and Development provides perspective, covers recent technological developments, and discusses biomarker characterization and validation.

The chapters overview the areas where proper use of biomarkers can substantively impact drug development timelines and costs, enable the selection of better compounds, reduce late stage attrition, and facilitate personalized medicine. Contributing authors from the frontlines of industrial research and development present case studies of biomarkers that have helped and hindered decision making. The new edition updates existing information with developments in genomic sequencing and application of large data sets into pre-clinical and clinical testing; and introduces substantial new materials on data mining, economics, and decision making.

With such significant expansion and revision, Biomarkers in Drug Discovery and Development, Second Edition remains a key resource for biotechnology and major pharmaceutical companies, and their efforts to improve and expedite drug development.

Details zur Ausgabe

• Verlag: Wiley
• Erscheinungsdatum: 2020
• Sprache: Englisch
• ISBN 10: 1119187508
• ISBN 13: 9781119187509
• Einband: Gebundene Ausgabe
• Auflage: 2
• Anzahl der Seiten: 608
• Herausgeber: Rahbari Ramin, Van Niewaal Jonathan, Bleavins Michael R.
• Kontakt zum Hersteller: Wiley-VCH GmbH; product_safety@wiley.com; ; Boschstrasse 12; Weinheim; 69469; Deutschland